id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1975-N-0336-0077,FDA,FDA-1975-N-0336,"Letter from FDA CDER to Hyman, Phelps and McNamara, P.C.",Other,Letter(s),2016-08-22T04:00:00Z,2016,8,2016-08-22T04:00:00Z,,2016-08-22T18:14:59Z,,0,0,0900006482190241
FDA-1975-N-0336-0076,FDA,FDA-1975-N-0336,"Letter from Valeant Pharmaceuticals North America, LLC to FDA/CDER",Other,Letter(s),2016-06-03T04:00:00Z,2016,6,2016-06-03T04:00:00Z,,2017-12-05T20:14:21Z,,0,0,090000648200e1ec
FDA-1975-N-0336-0075,FDA,FDA-1975-N-0336,"Letter from Hyman, Phelps and McNamara, P.C. to FDA DDM",Other,Letter(s),2016-06-01T04:00:00Z,2016,6,2016-06-01T04:00:00Z,,2016-06-01T17:46:20Z,,0,0,0900006482005b7c
FDA-1975-N-0336-0074,FDA,FDA-1975-N-0336,"FDA Notice to Docket Regarding Librax, DESI 10837",Other,Memo,2016-05-24T04:00:00Z,2016,5,2016-05-24T04:00:00Z,,2016-06-06T20:14:14Z,,0,0,0900006481fe8f19